7.95
前日終値:
$8.50
開ける:
$8.48
24時間の取引高:
3.75M
Relative Volume:
3.22
時価総額:
$1.06B
収益:
$247.00M
当期純損益:
$-249.00M
株価収益率:
-2.5728
EPS:
-3.09
ネットキャッシュフロー:
$-267.00M
1週間 パフォーマンス:
-7.77%
1か月 パフォーマンス:
-11.96%
6か月 パフォーマンス:
-47.94%
1年 パフォーマンス:
-47.59%
Arcus Biosciences Inc Stock (RCUS) Company Profile
名前
Arcus Biosciences Inc
セクター
電話
(510) 694-6200
住所
3928 POINT EDEN WAY, HAYWARD, CA
RCUS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RCUS
Arcus Biosciences Inc
|
7.95 | 1.06B | 247.00M | -249.00M | -267.00M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
2024-10-21 | 開始されました | H.C. Wainwright | Neutral |
2024-10-08 | 開始されました | Wells Fargo | Overweight |
2022-11-18 | 開始されました | BofA Securities | Neutral |
2022-10-11 | 開始されました | Morgan Stanley | Overweight |
2021-10-15 | 再開されました | BTIG Research | Buy |
2020-11-24 | 開始されました | Berenberg | Buy |
2020-11-23 | 開始されました | Evercore ISI | Outperform |
2020-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
2020-03-04 | 開始されました | Barclays | Overweight |
2019-11-12 | 開始されました | SunTrust | Buy |
2019-09-27 | 開始されました | Mizuho | Buy |
2019-05-24 | 再開されました | Citigroup | Buy |
2018-10-09 | 開始されました | Wedbush | Outperform |
2018-04-09 | 開始されました | Citigroup | Buy |
2018-04-09 | 開始されました | Goldman | Neutral |
2018-04-09 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Arcus Biosciences Inc (RCUS) 最新ニュース
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
When the Price of (RCUS) Talks, People Listen - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Bank of America Corp DE - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treat - GuruFocus
Transcript : Arcus Biosciences, Inc.Special Call - MarketScreener
Arcus Biosciences Presents Promising Phase 1/1b Trial Data - TipRanks
Two Sigma Investments LP Purchases 11,027 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News - GuruFocus
Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response - marketscreener.com
ProShare Advisors LLC Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (NYSE:RCUS) Shares Down 8.6% – Here’s What Happened - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases 9,016 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Deutsche Bank AG Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market - Investing.com
Lazard Asset Management LLC Has $93,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy - ACS Publications
Recent Investment Analysts’ Ratings Changes for Arcus Biosciences (RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Northern Trust Corp - Defense World
Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17% - simplywall.st
Trading (RCUS) With Integrated Risk Controls - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Sells 6,265 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $22.00 - Defense World
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Has Weak Forecast for RCUS FY2025 Earnings - Defense World
HC Wainwright Predicts Weaker Earnings for Arcus Biosciences - Defense World
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Wedbush Decreases Earnings Estimates for Arcus Biosciences - Defense World
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) - GuruFocus
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Arcus Biosciences Inc (RCUS) 財務データ
収益
当期純利益
現金流量
EPS
Arcus Biosciences Inc (RCUS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
ROSEN TERRY J | Chief Executive Officer |
Feb 27 '25 |
Buy |
10.18 |
19,800 |
201,465 |
2,554,160 |
GILEAD SCIENCES, INC. | 10% Owner |
Feb 18 '25 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
31,424,760 |
Goeltz II Robert C. | Chief Financial Officer |
Dec 31 '24 |
Sale |
15.00 |
3,594 |
53,910 |
60,138 |
大文字化:
|
ボリューム (24 時間):